Recursion Pharmaceuticals (RXRX) Stock Price
$4.94 0%
to add to portfolio
AI Score
-
Alternative
6 -
Fundamental
3 -
Technical
3
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Recursion Pharmaceuticals, AI stock picks, stock alerts and much more.
RXRX AI Stock Analysis
Financial Performance
The financial performance of Recursion Pharmaceuticals shows mixed results. The company's revenue has shown a strong upward trend, with a significant increase of 226.9% from the previous quarter and a modest year-over-year growth of 2.3%. However, gross profit and operating income are both in negative territory, indicating that the firm is currently not profitable. The EBITDA ratio also suggests that the company is struggling financially.
Stock Price
The stock price for Recursion Pharmaceuticals has been on a downward trend with a decline of -36.7% year over year and -5.4% in the last month alone. This suggests bearish sentiment among investors. The RSI value at 40.36 indicates that the stock is nearing oversold territory which may signal potential buying opportunity for contrarian investors or further selling pressure if it moves below 30 level.
Alternative Data Signals
In terms of alternative data signals, web traffic to Recursion Pharmaceuticals' site has increased significantly by 50.9% YoY indicating increased interest in the company's activities or offerings which could potentially translate into future business opportunities or investor interest. Their social media presence has also grown substantially over the last three months which can be seen as positive sign for brand visibility and engagement but this doesn't necessarily translate into better financial performance or stock price appreciation.
Conclusion
In conclusion, despite some positive indicators such as increasing revenues and growing web traffic and social media followers, Recursion Pharmaceuticals' overall financial health appears weak due to its lack of profitability indicated by negative gross profit, operating income and low EBITDA ratio along with declining stock price trends suggesting bearish market sentiment towards Recursion Pharmaceuticals' stock at this time.
Note: This AI Stock Analysis is based on data as of August 23. Our members can refresh and get access to an up-to-date AI stock analysis.
Sign up
Recursion Pharmaceuticals (RXRX) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Recursion Pharmaceuticals (RXRX), currently trading at $4.94, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About RXRX
-
Recursion Pharmaceuticals, Inc.
-
Symbol
RXRX
-
Market
NASDAQ
-
Industry
Biotechnology
-
Market Cap
2.1B
Similar Stocks
 |
Catalyst Pharmaceuticals CPRX |
$21.08 2.5% |
8 |
 |
Inovio Pharmaceuticals INO |
$1.96 2.6% |
3 |
 |
Moderna MRNA |
$27.12 3.4% |
3 |
 |
Anavex Life Sciences AVXL |
$9.53 0.2% |
5 |
 |
BridgeBio Pharma BBIO |
$49.08 2.3% |
6 |
News
RXRX Alternative Data
Web Traffic
Recursion Pharmaceuticals receives an estimated 72205 monthly visitors to recursion.com.
-
Web Traffic
72205
-
Change from Previous Month
4.9%
-
3 Month Change
54.7%
-
YoY Change
54.7%
Facebook Engagement
Recursion Pharmaceuticals has engaged 64 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
64
-
Daily Change
4.9%
-
1 Month Change
178.3%
-
3 Month Change
611.1%
-
YoY Change
611.1%
Youtube Subscribers
Recursion Pharmaceuticals has 11,200 subscribers on its main Youtube channel, up by 182.8% over the last month.
-
Youtube Subscribers
11200
-
Daily Change
2.8%
-
1 Month Change
182.8%
-
3 Month Change
198.7%
-
YoY Change
198.7%
Job Postings
Recursion Pharmaceuticals has an estimated 29 open job postings, which is down -3.3% over the last month.
-
Job Postings
29
-
Daily Change
0%
-
1 Month Change
3.3%
-
3 Month Change
123.1%
-
YoY Change
123.1%
Reddit Mentions
Recursion Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
100%
-
3 Month Change
0%
Twitter Followers
Recursion Pharmaceuticals has 15,177 Twitter Followers on its main Twitter (also known as X) account, which is up by 1.6% over the last month.
-
Twitter Followers
15177
-
Daily Change
0.1%
-
1 Month Change
1.6%
-
3 Month Change
6.3%
-
YoY Change
6.3%
Business Outlook
According to employee reviews, the business outlook among employees at Recursion Pharmaceuticals is 53 out of 100 (neutral).
-
Business Outlook
53
-
Change from Previous Month
10.2%
-
3 Month Change
29.3%
-
YoY Change
29.3%
News Mentions
Recursion Pharmaceuticals was mentioned 1 times in the news yesterday.
-
News Mentions
1
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Employees
According to LinkedIn, Recursion Pharmaceuticals has 580 employees.
-
LinkedIn Employees
580
-
Daily Change
2%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
RXRX Financials
RXRX Key Metrics
-
Total Revenue
$14.7M
-
Net Income
-$202.5M
-
Earnings per Share
-$0.5
-
Free cash flow
-$133.8M
-
EBITDA
-$191.4M
-
EBITDA Ratio
-12.9785
-
Total Assets
$1.3B
RXRX 2-year Revenue & Income
RXRX 2-year Free Cash Flow
RXRX Technicals
RXRX SMA
RXRX RSI
FAQ
What's the current price of Recursion Pharmaceuticals (RXRX) Stock?
The price of an Recursion Pharmaceuticals (RXRX) share is $4.94.
What's the market cap of Recursion Pharmaceuticals?
The current market cap of Recursion Pharmaceuticals is 2.1B.
Should I buy or sell RXRX?
Recursion Pharmaceuticals shows several positive indicators, but they aren’t strong enough to warrant a buy recommendation. At its current price, Recursion Pharmaceuticals is better viewed as a hold or accumulate position while waiting for further developments.
Is Recursion Pharmaceuticals a good investment?
The current analysis of Recursion Pharmaceuticals' fundamentals, technical aspects, and alternative data insights indicates a neutral outlook on the stock. While there are promising elements in Recursion Pharmaceuticals' portfolio, the presence of equal risks and opportunities suggests that it might not drive significant gains or losses at this moment.
Is now a good time to buy Recursion Pharmaceuticals (RXRX) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, the outlook for Recursion Pharmaceuticals stock is currently neutral, suggesting a cautious approach might be wise.
What are some stocks similar to Recursion Pharmaceuticals (RXRX) that investors often compare it to?
Recursion Pharmaceuticals (RXRX) is often compared to similar stocks such as Catalyst Pharmaceuticals, Inovio Pharmaceuticals, Moderna, Anavex Life Sciences and BridgeBio Pharma.
What is the forecast for Recursion Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Recursion Pharmaceuticals' stock price to be around $4.85 in 2026. Starting from the current price of $4.94, this represents a 1.8% change in price, indicating a neutral outlook for the stock.
How to buy Recursion Pharmaceuticals (RXRX) Stock?
Recursion Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Recursion Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.